{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T05:00:36Z","timestamp":1785474036137,"version":"3.56.0"},"reference-count":110,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T00:00:00Z","timestamp":1785283200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"the Project of the Beijing Rural Revitalization Agricultural Science and Technology Project","award":["Grant No. NY2601060226"],"award-info":[{"award-number":["Grant No. NY2601060226"]}]},{"name":"the Project of the Beijing Academy of Agriculture and Forestry Science","award":["Grant No. KJCX20230213"],"award-info":[{"award-number":["Grant No. KJCX20230213"]}]},{"award":["Grant No. KJCX20230213"],"award-info":[{"award-number":["Grant No. KJCX20230213"]}],"id":[{"id":"https:\/\/ror.org\/04trzn023","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Human epidermal growth factor receptor 2 (HER2) and trophoblast cell surface antigen 2 (Trop-2) are tumor-associated antigens widely overexpressed in multiple malignant tumors, which drive malignant proliferation, invasion, metastasis, and therapeutic resistance by activating key downstream signaling pathways. Antibody\u2013drug conjugates (ADCs) targeting HER2 and Trop-2 leverage their antigen-specific binding capacity to achieve precise targeted delivery of cytotoxic drugs, representing a significant breakthrough in solid tumor therapy. This review systematically outlines the biological functions and carcinogenic mechanisms of HER2 and Trop-2, focusing on the latest research and development progress of related ADCs. We also summarize and analyze key clinical data and application prospects in breast cancer (BC), gastric cancer (GC), non-small cell lung cancer (NSCLC), and urothelial carcinoma (UC), while also delving into the challenges and future directions within this field.<\/jats:p>","DOI":"10.3390\/ph19081194","type":"journal-article","created":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T17:01:46Z","timestamp":1785344506000},"page":"1194","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Antibody\u2013Drug Conjugates Targeting HER2 and Trop-2: A New Force in Precision Treatment for Solid Tumors"],"prefix":"10.3390","volume":"19","author":[{"given":"Zhaoling","family":"Jiang","sequence":"first","affiliation":[{"name":"College of Animal Science and Technology, Beijing University of Agriculture, Beijing 102206, China"},{"name":"Institute of Animal Husbandry and Veterinary Medicine, Beijing Academy of Agriculture and Forestry Sciences, Beijing 100097, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Mei","sequence":"additional","affiliation":[{"name":"Institute of Animal Husbandry and Veterinary Medicine, Beijing Academy of Agriculture and Forestry Sciences, Beijing 100097, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1909-2422","authenticated-orcid":false,"given":"Xueze","family":"Lyu","sequence":"additional","affiliation":[{"name":"Beijing General Animal Husbandry Station, Beijing 100107, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-6677-3994","authenticated-orcid":false,"given":"Zhenyi","family":"Liu","sequence":"additional","affiliation":[{"name":"Institute of Animal Husbandry and Veterinary Medicine, Beijing Academy of Agriculture and Forestry Sciences, Beijing 100097, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihua","family":"Li","sequence":"additional","affiliation":[{"name":"Institute of Animal Husbandry and Veterinary Medicine, Beijing Academy of Agriculture and Forestry Sciences, Beijing 100097, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-5849-5328","authenticated-orcid":false,"given":"Baozhu","family":"Xing","sequence":"additional","affiliation":[{"name":"Institute of Animal Husbandry and Veterinary Medicine, Beijing Academy of Agriculture and Forestry Sciences, Beijing 100097, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Liu","sequence":"additional","affiliation":[{"name":"Institute of Animal Husbandry and Veterinary Medicine, Beijing Academy of Agriculture and Forestry Sciences, Beijing 100097, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gebin","family":"Li","sequence":"additional","affiliation":[{"name":"Small Animal Department, College of Veterinary Medicine, China Agricultural University, Beijing 100193, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongjun","family":"Wang","sequence":"additional","affiliation":[{"name":"Institute of Animal Husbandry and Veterinary Medicine, Beijing Academy of Agriculture and Forestry Sciences, Beijing 100097, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,29]]},"reference":[{"key":"ref_1","first-page":"165","article-title":"Antibody-drug conjugates: Smart chemotherapy delivery across tumor histologies","volume":"72","author":"Tarantino","year":"2022","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"e2302377","DOI":"10.1002\/advs.202302377","article-title":"A HER2-targeted antibody-drug conjugate, RC48-ADC, exerted promising antitumor efficacy and safety with intravesical instillation in preclinical models of bladder cancer","volume":"10","author":"Hong","year":"2023","journal-title":"Adv. Sci."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"e10677","DOI":"10.1002\/btm2.10677","article-title":"Antibody drug conjugates in the clinic","volume":"9","author":"Udofa","year":"2024","journal-title":"Bioeng. Transl. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.apsb.2024.12.036","article-title":"Resistance to antibody-drug conjugates: A review","volume":"15","author":"Li","year":"2025","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1136\/bmj.2.2746.353","article-title":"Address in pathology, on chemotherapy: Delivered before the Seventeenth International Congress of Medicine","volume":"2","author":"Ehrlich","year":"1913","journal-title":"BMJ"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"155627","DOI":"10.1016\/j.prp.2024.155627","article-title":"Immunogenicity of monoclonal antibody: Causes, consequences, and control strategies","volume":"263","author":"Asmani","year":"2024","journal-title":"Pathol. Res. Pract."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/s41571-021-00470-8","article-title":"Unlocking the potential of antibody-drug conjugates for cancer therapy","volume":"18","author":"Drago","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1046\/j.1523-1747.1999.00620.x","article-title":"Immune complexes from vasculitis patients bind to endothelial Fc receptors independent of the allelic polymorphism of FcgammaRIIa","volume":"113","author":"Fischer","year":"1999","journal-title":"J. Investig. Dermatol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e132","DOI":"10.1542\/peds.2008-2617","article-title":"Failure to predict hemolysis and hyperbilirubinemia by IgG subclass in blood group A or B infants born to group O mothers","volume":"123","author":"Kaplan","year":"2009","journal-title":"Pediatrics"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1007\/s11912-022-01266-4","article-title":"Bystander effect of antibody-drug conjugates: Fact or fiction?","volume":"24","author":"Giugliano","year":"2022","journal-title":"Curr. Oncol. Rep."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1002\/cpt.2291","article-title":"Exposure-Response Relationships in Patients with HER2-Positive Metastatic Breast Cancer and Other Solid Tumors Treated with Trastuzumab Deruxtecan","volume":"110","author":"Yin","year":"2021","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1158\/1535-7163.MCT-22-0375","article-title":"Antibody-Drug Conjugate Sacituzumab Govitecan Drives Efficient Tissue Penetration and Rapid Intracellular Drug Release","volume":"22","author":"Kopp","year":"2023","journal-title":"Mol. Cancer Ther."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s13045-022-01397-y","article-title":"Payload diversification: A key step in the development of antibody-drug conjugates","volume":"16","author":"Conilh","year":"2023","journal-title":"J. Hematol. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"102670","DOI":"10.1016\/j.ctrv.2023.102670","article-title":"Current and emerging treatment approaches for hormone receptor-positive\/human epidermal growth factor receptor 2-negative metastatic breast cancer","volume":"123","author":"Jhaveri","year":"2024","journal-title":"Cancer Treat. Rev."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/s41571-023-00850-2","article-title":"Exploring the next generation of antibody-drug conjugates","volume":"21","author":"Tsuchikama","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Lu, J., Jiang, F., Lu, A., and Zhang, G. (2016). Linkers having a crucial role in antibody-drug conjugates. Int. J. Mol. Sci., 17.","DOI":"10.3390\/ijms17040561"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"100204","DOI":"10.1016\/j.esmoop.2021.100204","article-title":"Sacituzumab govitecan and trastuzumab deruxtecan: Two new antibody-drug conjugates in the breast cancer treatment landscape","volume":"6","author":"Adams","year":"2021","journal-title":"ESMO Open"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1158\/1535-7163.MCT-23-0359","article-title":"Design and evaluation of phosphonamidate-linked exatecan constructs for highly loaded, stable, and efficacious antibody-drug conjugates","volume":"23","author":"Schmitt","year":"2024","journal-title":"Mol. Cancer Ther."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"107917","DOI":"10.1016\/j.pharmthera.2021.107917","article-title":"Stepping forward in antibody-drug conjugate development","volume":"229","author":"Jin","year":"2022","journal-title":"Pharmacol. Ther."},{"key":"ref_20","first-page":"104241","article-title":"Antibody-drug conjugates: Prospects for the next generation","volume":"29","author":"Grairi","year":"2024","journal-title":"Drug Discov. Ther."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/cac2.12517","article-title":"Development of antibody-drug conjugates in cancer: Overview and prospects","volume":"44","author":"Ruan","year":"2024","journal-title":"Cancer Commun."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1126\/science.2999974","article-title":"Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene","volume":"230","author":"Coussens","year":"1985","journal-title":"Science"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1056\/NEJMcibr1909386","article-title":"HER2 and breast cancer: A phenomenal success story","volume":"381","author":"Hayes","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"R2","DOI":"10.1186\/bcr2217","article-title":"Phosphoinositide 3-kinase targeting by the beta galactoside binding protein cytokine negates akt gene expression and leads aggressive breast cancer cells to apoptotic death","volume":"11","author":"Wells","year":"2009","journal-title":"Breast Cancer Res."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Kirouac, D.C., Du, J., Lahdenranta, J., Onsum, M.D., Nielsen, U.B., Schoeberl, B., and McDonagh, C.F. (2016). HER2+ cancer cell dependence on PI3K vs. MAPK signaling axes is determined by expression of EGFR, ERBB3 and CDKN1B. PLoS Comput. Biol., 12.","DOI":"10.1371\/journal.pcbi.1004827"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e2400879","DOI":"10.1200\/PO-24-00879","article-title":"Testing and Interpretation of Human Epidermal Growth Factor Receptor 2 Protein Expression and ERBB2 Gene Amplification in Advanced Urothelial Carcinoma","volume":"9","author":"Koshkin","year":"2025","journal-title":"JCO Precis. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1007\/s00428-025-04057-x","article-title":"Clinicopathological characteristics and prognostic significance of HER2 status evaluation in patients with urothelial carcinoma: A retrospective single-center experience in China","volume":"488","author":"Yang","year":"2026","journal-title":"Virchows Arch."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"102154","DOI":"10.1016\/j.xcrm.2025.102154","article-title":"Proteogenomic analysis of the CALGB 40601 (Alliance) HER2+ breast cancer neoadjuvant trial reveals resistance biomarkers","volume":"6","author":"Jaehnig","year":"2025","journal-title":"Cell Rep. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"oyaf081","DOI":"10.1093\/oncolo\/oyaf081","article-title":"Exploring immune activation patterns in HER2-low and HER2-ultralow breast cancer subtypes","volume":"30","author":"Santarpia","year":"2025","journal-title":"Oncologist"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1002\/cam4.432","article-title":"HER2 as a target in invasive urothelial carcinoma","volume":"4","author":"Bellmunt","year":"2015","journal-title":"Cancer Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1126\/science.3798106","article-title":"Human breast cancer: Correlation of relapse and survival with amplification of the HER-2\/neu oncogene","volume":"235","author":"Slamon","year":"1987","journal-title":"Science"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"e222646","DOI":"10.1148\/radiol.222646","article-title":"Multiparametric MRI and radiomics for the prediction of HER2-zero, -low, and -positive breast cancers","volume":"308","author":"Ramtohul","year":"2023","journal-title":"Radiology"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41573-022-00579-0","article-title":"Targeting HER2-positive breast cancer: Advances and future directions","volume":"22","author":"Swain","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"110160","DOI":"10.1016\/j.celrep.2021.110160","article-title":"MAL2 mediates the formation of stable HER2 signaling complexes within lipid raft-rich membrane protrusions in breast cancer cells","volume":"37","author":"Jeong","year":"2021","journal-title":"Cell Rep."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1200\/JCO.2007.14.8957","article-title":"Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2\/neu-positive metastatic breast cancer","volume":"26","author":"Musolino","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1158\/1535-7163.MCT-20-0190","article-title":"A novel HER2-targeted antibody-drug conjugate offers the possibility of clinical dosing at trastuzumab-equivalent exposure levels","volume":"19","author":"Barfield","year":"2020","journal-title":"Mol. Cancer Ther."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1158\/1078-0432.CCR-18-1976","article-title":"HER2-overexpressing\/amplified breast cancer as a testing ground for antibody-drug conjugate drug development in solid tumors","volume":"26","author":"Pegram","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"5329","DOI":"10.1158\/0008-5472.CAN-15-1610","article-title":"SLC46A3 is required to transport catabolites of noncleavable antibody maytansine conjugates from the lysosome to the cytoplasm","volume":"75","author":"Hamblett","year":"2015","journal-title":"Cancer Res."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"4478","DOI":"10.1158\/1078-0432.CCR-20-4557","article-title":"FDA approval summary: Fam-trastuzumab deruxtecan-nxki for the treatment of unresectable or metastatic HER2-positive breast cancer","volume":"27","author":"Narayan","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1209124","article-title":"Trastuzumab emtansine for HER2-positive advanced breast cancer","volume":"367","author":"Verma","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/S1470-2045(14)70178-0","article-title":"Trastuzumab emtansine versus treatment of physician\u2019s choice for pretreated HER2-positive advanced breast cancer (TH3RESA): A randomised, open-label, phase 3 trial","volume":"15","author":"Krop","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1007\/s10120-014-0402-y","article-title":"HER2 screening data from ToGA: Targeting HER2 in gastric and gastroesophageal junction cancer","volume":"18","author":"Bang","year":"2015","journal-title":"Gastric Cancer"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1001\/jamaoncol.2020.1796","article-title":"Efficacy and safety of trastuzumab emtansine plus capecitabine vs trastuzumab emtansine alone in patients with previously treated ERBB2 (HER2)-positive metastatic breast cancer: A phase 1 and randomized phase 2 trial","volume":"6","author":"Lorenzen","year":"2020","journal-title":"JAMA Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1158\/1078-0432.CCR-18-1590","article-title":"Trastuzumab emtansine (T-DM1) in patients with previously treated HER2-overexpressing metastatic non-small cell lung cancer: Efficacy, safety, and biomarkers","volume":"25","author":"Peters","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ejca.2021.11.021","article-title":"Trastuzumab emtansine for patients with non-small cell lung cancer positive for human epidermal growth factor receptor 2 exon-20 insertion mutations","volume":"162","author":"Iwama","year":"2022","journal-title":"Eur. J. Cancer"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s13058-021-01459-y","article-title":"Implementing antibody-drug conjugates (ADCs) in HER2-positive breast cancer: State of the art and future directions","volume":"23","author":"Ferraro","year":"2021","journal-title":"Breast Cancer Res."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0140-6736(22)02420-5","article-title":"Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: Updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial","volume":"401","author":"Hurvitz","year":"2023","journal-title":"Lancet"},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Conilh, L., Fournet, G., Fourmaux, E., Murcia, A., Matera, E.L., Joseph, B., Dumontet, C., and Viricel, W. (2021). Exatecan Antibody Drug Conjugates Based on a Hydrophilic Polysarcosine Drug-Linker Platform. Pharmaceuticals, 14.","DOI":"10.3390\/ph14030247"},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Nie, C., Xu, W., Guo, Y., Gao, X., Lv, H., Chen, B., Wang, J., Liu, Y., Zhao, J., and Wang, S. (2023). Immune checkpoint inhibitors enhanced the antitumor efficacy of disitamab vedotin for patients with HER2-positive or HER2-low advanced or metastatic gastric cancer: A multicenter real-world study. BMC Cancer, 23.","DOI":"10.1186\/s12885-023-11735-z"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1038\/s41591-024-02992-x","article-title":"Trastuzumab deruxtecan in HER2-positive advanced gastric cancer: Exploratory biomarker analysis of the randomized, phase 2 DESTINY-Gastric01 trial","volume":"30","author":"Shitara","year":"2024","journal-title":"Nat. Med."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/S1470-2045(23)00215-2","article-title":"Trastuzumab deruxtecan in patients in the USA and Europe with HER2-positive advanced gastric or gastroesophageal junction cancer with disease progression on or after a trastuzumab-containing regimen (DESTINY-Gastric02): Primary and updated analyses from a single-arm, phase 2 study","volume":"24","author":"Smyth","year":"2023","journal-title":"Lancet Oncol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1056\/NEJMoa2112431","article-title":"Trastuzumab deruxtecan in HER2-mutant non-small-cell lung cancer","volume":"386","author":"Li","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"4852","DOI":"10.1200\/JCO.23.01361","article-title":"Trastuzumab deruxtecan in patients with HER2-mutant metastatic non-small-cell lung cancer: Primary results from the randomized, phase II DESTINY-Lung02 trial","volume":"41","author":"Goto","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1002\/cac2.12214","article-title":"Efficacy and safety of a novel anti-HER2 therapeutic antibody RC48 in patients with HER2-overexpressing, locally advanced or metastatic gastric or gastroesophageal junction cancer: A single-arm phase II study","volume":"41","author":"Peng","year":"2021","journal-title":"Cancer Commun."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"103830","DOI":"10.1016\/j.breast.2024.103830","article-title":"Unveiling the future of breast cancer therapy: Cutting-edge antibody-drug conjugate strategies and clinical outcomes","volume":"78","author":"Sun","year":"2024","journal-title":"Breast"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1158\/1535-7163.MCT-25-0875","article-title":"Capivasertib combines with trastuzumab deruxtecan to enhance anti-tumour activity in HER2-positive and HER2-low tumours","volume":"25","author":"Bashi","year":"2026","journal-title":"Mol. Cancer Ther."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1007\/s12282-020-01153-5","article-title":"Development and biological assessment of MMAE-trastuzumab antibody-drug conjugates (ADCs)","volume":"28","author":"Yaghoubi","year":"2021","journal-title":"Breast Cancer"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1080\/10717544.2022.2069883","article-title":"Disitamab vedotin: A novel antibody-drug conjugate for cancer therapy","volume":"29","author":"Shi","year":"2022","journal-title":"Drug Deliv."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.ejps.2016.08.015","article-title":"HER2-targeted antibody drug conjugates for ovarian cancer therapy","volume":"93","author":"Jiang","year":"2016","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1002\/cac2.12577","article-title":"Disitamab vedotin, a HER2-directed antibody-drug conjugate, in patients with HER2-overexpression and HER2-low advanced breast cancer: A phase I\/Ib study","volume":"44","author":"Wang","year":"2024","journal-title":"Cancer Commun."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"e2026921","DOI":"10.1001\/jamanetworkopen.2020.26921","article-title":"Association of circulating tumor DNA with disease-free survival in breast cancer: A systematic review and meta-analysis","volume":"3","author":"Cullinane","year":"2020","journal-title":"JAMA Netw. Open"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"102415","DOI":"10.1016\/j.eclinm.2023.102415","article-title":"Disitamab vedotin (RC48) plus toripalimab for HER2-expressing advanced gastric or gastroesophageal junction and other solid tumours: A multicentre, open label, dose escalation and expansion phase 1 trial","volume":"68","author":"Wang","year":"2024","journal-title":"eClinicalMedicine"},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Qu, F., Lu, R., Wu, X., Wu, Q., Zhao, M., Li, H., Yuan, Y., Han, Z., Cai, D., and Huang, X. (2024). Efficacy and safety of RC48-ADC in HER2-positive and HER2-low metastatic breast cancer: A multicenter, real-world study. Front. Oncol., 14.","DOI":"10.3389\/fonc.2024.1435485"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1158\/1078-0432.CCR-20-2488","article-title":"Open-label, multicenter, phase II study of RC48-ADC, a HER2-targeting antibody-drug conjugate, in patients with locally advanced or metastatic urothelial carcinoma","volume":"27","author":"Sheng","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"CT175","DOI":"10.1158\/1538-7445.AM2023-CT175","article-title":"Abstract CT175: Safety, tolerability, pharmacokinetics, and antitumor activity of SHR-A1811 in HER2-expressing\/mutated advanced solid tumors: A global phase 1, multi-center, first-in-human study","volume":"83","author":"Yao","year":"2023","journal-title":"Cancer Res."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1200\/JCO.24.00529","article-title":"Trastuzumab duocarmazine in pretreated human epidermal growth factor receptor 2\u2013positive advanced or metastatic breast cancer: An open-label, randomized, phase III trial (TULIP)","volume":"43","author":"Turner","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"10479","DOI":"10.1038\/s41598-018-28533-4","article-title":"Pre-clinical pharmacology and mechanism of action of SG3199, the pyrrolobenzodiazepine (PBD) dimer warhead component of antibody-drug conjugate (ADC) payload tesirine","volume":"8","author":"Hartley","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1158\/1535-7163.MCT-20-0222","article-title":"The Role of Specific ATP-Binding Cassette Transporters in the Acquired Resistance to Pyrrolobenzodiazepine Dimer-Containing Antibody-Drug Conjugates","volume":"19","author":"Corbett","year":"2020","journal-title":"Mol. Cancer Ther."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"9280","DOI":"10.1158\/0008-5472.CAN-08-1776","article-title":"Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate","volume":"68","author":"Phillips","year":"2008","journal-title":"Cancer Res."},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Yu, J., Fang, T., Yun, C., Liu, X., and Cai, X. (2022). Antibody-Drug Conjugates Targeting the Human Epidermal Growth Factor Receptor Family in Cancers. Front. Mol. Biosci., 9.","DOI":"10.3389\/fmolb.2022.847835"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1200\/JCO.22.02912","article-title":"Efficacy and Safety of Disitamab Vedotin in Patients with Human Epidermal Growth Factor Receptor 2-Positive Locally Advanced or Metastatic Urothelial Carcinoma: A Combined Analysis of Two Phase II Clinical Trials","volume":"42","author":"Sheng","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.annonc.2025.02.011","article-title":"Efficacy and safety of neoadjuvant SHR-A1811 with or without pyrotinib in women with locally advanced or early HER2-positive breast cancer: A randomized, open-label, phase II trial","volume":"36","author":"Li","year":"2025","journal-title":"Ann. Oncol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"111682","DOI":"10.1016\/j.ejmech.2019.111682","article-title":"Novel HER2-Targeting Antibody-Drug Conjugates of Trastuzumab Beyond T-DM1 in Breast Cancer: Trastuzumab Deruxtecan(DS-8201a) and (Vic-)Trastuzumab Duocarmazine (SYD985)","volume":"183","author":"Xu","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"5909","DOI":"10.1021\/acs.molpharmaceut.4c00848","article-title":"Trop-2-targeted molecular imaging in solid tumors: Current advances and future outlook","volume":"21","author":"Liu","year":"2024","journal-title":"Mol. Pharm."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1002\/(SICI)1097-0215(19980119)75:2<324::AID-IJC24>3.0.CO;2-B","article-title":"Cloning of the murine Trop-2 gene: Conservation of a PIP2-binding sequence in the cytoplasmic domain of Trop-2","volume":"75","author":"Fornaro","year":"1998","journal-title":"Int. J. Cancer"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"5147","DOI":"10.1073\/pnas.78.8.5147","article-title":"Human trophoblast cell-surface antigens defined by monoclonal antibodies","volume":"78","author":"Lipinski","year":"1981","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.2147\/OTT.S162447","article-title":"Targeting Trop-2 in solid tumors: Future prospects","volume":"12","author":"Zaman","year":"2019","journal-title":"OncoTargets Ther."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.pep.2013.07.006","article-title":"Biochemical and preliminary X-ray characterization of the tumor-associated calcium signal transducer 2 (Trop-2) ectodomain","volume":"91","author":"Vidmar","year":"2013","journal-title":"Protein Expr. Purif."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1186\/1476-4598-9-253","article-title":"Trop-2 expression contributes to tumor pathogenesis by activating the ERK MAPK pathway","volume":"9","author":"Cubas","year":"2010","journal-title":"Mol. Cancer"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"4197","DOI":"10.1158\/1078-0432.CCR-15-1701","article-title":"Trop-2 induces tumor growth through AKT and determines sensitivity to AKT inhibitors","volume":"22","author":"Guerra","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s40364-024-00633-6","article-title":"Trop-2-targeted therapy in breast cancer","volume":"12","author":"Hu","year":"2024","journal-title":"Biomark. Res."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1101\/gad.196451.112","article-title":"Regulated proteolysis of Trop-2 drives epithelial hyperplasia and stem cell self-renewal via \u03b2-catenin signaling","volume":"26","author":"Stoyanova","year":"2012","journal-title":"Genes Dev."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.21037\/tau-22-457","article-title":"Comparison of molecular profiles of upper tract urothelial carcinoma vs. urinary bladder cancer in the era of targeted therapy: A narrative review","volume":"11","author":"Tomiyama","year":"2022","journal-title":"Transl. Androl. Urol."},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Lombardi, P., Filetti, M., Falcone, R., Altamura, V., Paroni Sterbini, F., Bria, E., Fabi, A., Giannarelli, D., Scambia, G., and Daniele, G. (2023). Overview of Trop-2 in cancer: From pre-clinical studies to future directions in clinical settings. Cancers, 15.","DOI":"10.3390\/cancers15061744"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"102672","DOI":"10.1016\/j.ctrv.2023.102672","article-title":"Breaking barriers in triple-negative breast cancer (TNBC): Unleashing the power of antibody-drug conjugates (ADCs)","volume":"123","author":"Dri","year":"2024","journal-title":"Cancer Treat. Rev."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1002\/ddr.21938","article-title":"Sophoraflavanone G suppresses the progression of triple-negative breast cancer via the inactivation of EGFR-PI3K-AKT signaling","volume":"83","author":"Cheng","year":"2022","journal-title":"Drug Dev. Res."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.urolonc.2023.06.006","article-title":"Antibody-drug conjugates for urothelial carcinoma","volume":"41","author":"Thomas","year":"2023","journal-title":"Urol. Oncol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1038\/s41523-022-00467-1","article-title":"Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer","volume":"8","author":"Rugo","year":"2022","journal-title":"npj Breast Cancer"},{"key":"ref_89","first-page":"188902","article-title":"Targeting Trop-2 in cancer: Recent research progress and clinical application","volume":"1878","author":"Qiu","year":"2023","journal-title":"BBA Rev. Cancer"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1158\/1535-7163.MCT-21-0206","article-title":"Datopotamab deruxtecan, a novel Trop-2-directed antibody-drug conjugate, demonstrates potent antitumor activity by efficient drug delivery to tumor cells","volume":"20","author":"Okajima","year":"2021","journal-title":"Mol. Cancer Ther."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"4405","DOI":"10.1158\/1078-0432.CCR-25-1388","article-title":"FDA Approval Summary: Datopotamab Deruxtecan-dlnk for Treatment of Patients with Unresectable or Metastatic, HR-Positive, HER2-Negative Breast Cancer","volume":"31","author":"Royce","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/s41698-024-00584-z","article-title":"A new TROP2-targeting antibody-drug conjugate shows potent antitumor efficacy in breast and lung cancers","volume":"8","author":"Zhou","year":"2024","journal-title":"npj Precis. Oncol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1158\/1535-7163.MCT-16-0431","article-title":"RN927C, a Site-Specific Trop-2 Antibody-Drug Conjugate (ADC) with Enhanced Stability, Is Highly Efficacious in Preclinical Solid Tumor Models","volume":"15","author":"Strop","year":"2016","journal-title":"Mol. Cancer Ther."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/j.ccell.2025.03.017","article-title":"Spatial determinants of antibody-drug conjugate SHR-A1811 efficacy in neoadjuvant treatment for HER2-positive breast cancer","volume":"43","author":"Ma","year":"2025","journal-title":"Cancer Cell"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1038\/s41698-026-01523-w","article-title":"Pan-cancer multi-omic integration of Trop2 reveals biological determinants and translational implications for ADC therapy","volume":"10","author":"Notini","year":"2026","journal-title":"npj Precis. Oncol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"e1480","DOI":"10.1093\/oncolo\/oyae168","article-title":"Genomic, immunologic, and prognostic associations of TROP2 (TACSTD2) expression in solid tumors","volume":"29","author":"Kareff","year":"2024","journal-title":"Oncologist"},{"key":"ref_97","first-page":"241","article-title":"Lidamycin-based targeted drugs for tumor therapy","volume":"31","author":"Xu","year":"2019","journal-title":"Chin. Bull. Life Sci."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1158\/1078-0432.CCR-25-3321","article-title":"Payload Diversification Overcomes Resistance and Guides Sequential Antibody-Drug Conjugate Therapy in Breast Cancer","volume":"32","author":"Rampa","year":"2026","journal-title":"Clin. Cancer Res."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"102720","DOI":"10.1016\/j.ctrv.2024.102720","article-title":"Clinical management, monitoring, and prophylaxis of adverse events of special interest associated with datopotamab deruxtecan","volume":"125","author":"Heist","year":"2024","journal-title":"Cancer Treat. Rev."},{"key":"ref_100","doi-asserted-by":"crossref","unstructured":"Tong, Y., Fan, X., Liu, H., and Liang, T. (2024). Advances in Trop-2 targeted antibody-drug conjugates for breast cancer: Mechanisms, clinical applications, and future directions. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1495675"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"100761","DOI":"10.1016\/j.drup.2021.100761","article-title":"Cross-resistance and drug sequence in prostate cancer","volume":"56","author":"Buck","year":"2021","journal-title":"Drug Resist. Updates"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"e2400898","DOI":"10.1200\/PO-24-00898","article-title":"Sequential Antibody-Drug Conjugate Therapy in Patients with Metastatic Breast Cancer Treated with Sacituzumab Govitecan and Trastuzumab Deruxtecan","volume":"9","author":"Mai","year":"2025","journal-title":"JCO Precis. Oncol."},{"key":"ref_103","first-page":"833","article-title":"Drug resistance to antibody-drug conjugates: Mechanisms, challenges, and perspectives","volume":"23","author":"Liu","year":"2026","journal-title":"Cancer Biol. Med."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"217900","DOI":"10.1016\/j.canlet.2025.217900","article-title":"Drug-tolerant persisting polyploid giant cancer cells mediate resistance to HER2-targeting antibody-drug conjugates","volume":"630","author":"Yazdi","year":"2025","journal-title":"Cancer Lett."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"101353","DOI":"10.1016\/j.drup.2026.101353","article-title":"Mechanisms of resistance to antibody-drug conjugates in breast cancer","volume":"85","author":"Cerci","year":"2026","journal-title":"Drug Resist. Updates"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s13045-025-01752-9","article-title":"Overcoming resistance to antibody-drug conjugates: From mechanistic insights to cutting-edge strategies","volume":"18","author":"Zhou","year":"2025","journal-title":"J. Hematol. Oncol."},{"key":"ref_107","doi-asserted-by":"crossref","unstructured":"Alradwan, I.A., Alnefaie, M.K., Al Fayez, N., Aodah, A.H., Majrashi, M.A., Alturki, M., Fallatah, M.M., Almughem, F.A., Tawfik, E.A., and Alshehri, A.A. (2025). Strategic and Chemical Advances in Antibody-Drug Conjugates. Pharmaceutics, 17.","DOI":"10.3390\/pharmaceutics17091164"},{"key":"ref_108","first-page":"321","article-title":"Future directions for antibody-drug conjugates in urothelial cancer","volume":"26","author":"Pirola","year":"2025","journal-title":"Expert Rev. Anticancer Ther."},{"key":"ref_109","doi-asserted-by":"crossref","unstructured":"Sabit, H., Abbas, S., El-Safoury, M.T., Madkour, E.M., Mahmoud, S., Abdel-Ghany, S., Albrahim, Y., Al-Dhuayan, I.S., Rashwan, S., and El-Hashash, A. (2025). Antibody-Drug Conjugates in Breast Cancer: Navigating Innovations, Overcoming Resistance, and Shaping Future Therapies. Biomedicines, 13.","DOI":"10.3390\/biomedicines13092227"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.jmoldx.2022.04.002","article-title":"Discordance between Immunohistochemistry and Erb-B2 Receptor Tyrosine Kinase 2 mRNA to Determine Human Epidermal Growth Factor Receptor 2 Low Status for Breast Cancer","volume":"24","author":"Xu","year":"2022","journal-title":"J. Mol. Diagn."}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/19\/8\/1194\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T04:42:31Z","timestamp":1785472951000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/19\/8\/1194"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,29]]},"references-count":110,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["ph19081194"],"URL":"https:\/\/doi.org\/10.3390\/ph19081194","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,29]]}}}